Test Price
3,000 AED✅ Home Collection Available
Noonan-RASopathies Panel Genetic Test in UAE | 3000 AED | 2026 DHA Guidelines
تحليل لوحة نونان ومتلازمات راس الجينية في الإمارات | 3000 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing. Covering 22 critical genes across the RAS-MAPK signaling pathway with clinically validated variant interpretation aligned to ACMG/AMP 2026 guidelines.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy available across all seven Emirates — Dubai, Abu Dhabi, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by qualified genetic counselors fluent in both English and Arabic, ensuring families understand pathogenic, likely pathogenic, and VUS findings.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We coordinate with all major UAE insurers including Daman, AXA, Oman Insurance, and Neuron.
الملخص التنفيذي: الفحص الجيني الشامل لتشخيص متلازمة نونان ومتلازمات راس المرتبطة بها باستخدام تقنية تسلسل الجيل التالي (NGS) المتطورة. تغطي هذه اللوحة التشخيصية 22 جيناً أساسياً في مسار RAS-MAPK للإشارات الخلوية. تُصدر النتائج خلال 3 إلى 4 أسابيع بدقة تشخيصية تصل إلى 99.9% عبر مختبر معتمد دولياً بشهادة ISO 9001:2015. الخدمة متوفرة في جميع أنحاء دولة الإمارات العربية المتحدة مع خدمة سحب الدم المنزلية المعتمدة. جلسات استشارة وراثية قبل وبعد الفحص متاحة باللغتين العربية والإنجليزية لضمان فهم كامل للنتائج وتأثيراتها السريرية على المريض والأسرة.
Test Overview
The Noonan-RASopathies Panel Genetic Test is a comprehensive next-generation sequencing assay designed to detect germline mutations across 22 genes implicated in the RAS-MAPK signaling pathway. This panel is the gold standard for molecular confirmation of Noonan syndrome, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome, and neurofibromatosis type 1 — collectively termed RASopathies. يُعد هذا الفحص المعيار الذهبي للتشخيص الجزيئي الدقيق. Clinically indicated for pediatric and adult patients presenting with dysmorphic features, congenital heart defects (especially pulmonic stenosis and hypertrophic cardiomyopathy), short stature, developmental delay, and failure to thrive, this test delivers actionable diagnostic clarity for families across the UAE.
Genes Analyzed (22-Gene Panel)
BRAF, CBL, HRAS, KAT6B, KRAS, LZTR1, MAP2K1, MAP2K2, NF1, NF2, NRAS, PTPN11, RAF1, RASA2, RIT1, SHOC2, SMARCB1, SOS1, SOS2, SPRED1, TSC1, TSC2
| Feature | Our NGS Panel (This Test) | Closest Alternative (Single-Gene Sequencing) |
|---|---|---|
| Precision | NGS with >99.9% analytical sensitivity across all 22 genes simultaneously; full exon coverage including splice-site junctions | Sanger sequencing of individual genes; limited to one gene per run; may miss deep intronic variants and mosaic mutations |
| Methodology | Next Generation Sequencing (NGS / Illumina Platform) with bioinformatic analysis aligned to GRCh38/hg38 reference genome | Capillary-based Sanger sequencing; no multiplexing capability; limited variant detection in low-level mosaicism |
| Turnaround Time | 3 to 4 Weeks | 8 to 16+ Weeks (cumulative across multiple genes) |
| Cost Efficiency | 3000 AED for all 22 genes — single comprehensive report | Individual gene tests may cost 2000–4000 AED each; cumulative cost prohibitive for full differential diagnosis |
| Clinical Utility | Differential diagnosis across all RASopathies simultaneously; actionable for surgical planning, oncologic surveillance, and genetic counseling | Stepwise testing delays definitive diagnosis; may miss overlapping phenotypes requiring multi-gene assessment |
Comparison based on 2026 clinical practice standards. Cumulative single-gene costs and TAT are representative estimates for the UAE diagnostic market.
Sample Requirements & Logistics
Accepted Sample Types
- Whole Blood (EDTA tube, 3–5 mL)
- Extracted DNA (minimum 1 µg, A260/280 ratio 1.8–2.0)
- One Drop Blood on FTA Card (room-temperature stable for transport)
Pre-Test Requirements
- Clinical history documenting dysmorphic features and relevant phenotype
- Genetic counseling session to draw a pedigree chart of affected family members
- Informed consent signed by patient or legal guardian
- No fasting required for blood draw
Logistics & Collection
- Home Collection: 8 AM – 11 PM, 7 days/week
- Cold-chain transport maintained throughout
- VIP Mobile Phlebotomy available upon request
- FTA card option ideal for remote/rural collection points
Physician Insight & Safety Protocol
Clinical Note from Dr. Prabhakar Reddy (DHA License: 61713011): "As a clinician who has interpreted hundreds of RASopathy panels, I emphasize that this test is most impactful when correlated with a detailed physical examination and family history. A negative NGS result does not exclude a clinical diagnosis of Noonan syndrome; non-coding variants, epigenetic factors, and as-yet-undiscovered genes may still contribute to the phenotype. I strongly recommend all families engage in pre-test and post-test genetic counseling to contextualize results within their unique clinical picture."
⚠ IMPORTANT CLINICAL NOTICE: Do not discontinue any prescribed medication without consulting your treating physician. This genetic test is diagnostic and informational; it does not replace ongoing medical management. Growth hormone therapy, cardiac medications, or any other prescribed treatments should continue as directed by your specialist pending test results.
Safety Information — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Medical Clearance)
- Acute febrile illness or active systemic infection at time of blood draw — may affect DNA quality
- Recent blood transfusion (within 4 weeks) — may cause sample chimerism and false results
- Active chemotherapy with known myelosuppression — may yield insufficient leukocyte DNA
- Known bone marrow transplant recipient — donor DNA may confound germline variant interpretation
- Inability to provide informed consent for genetic testing as per UAE Federal Decree-Law No. 41 of 2024
Emergency Red Flags — Seek Immediate Medical Attention
- New-onset cyanosis, severe shortness of breath, or syncope in a child with suspected RASopathy — may indicate critical cardiac decompensation
- Signs of increased intracranial pressure: severe headache, vomiting, lethargy, or bulging fontanelle in infants — risk with NF1-associated optic pathway gliomas
- Acute neurological deficit, seizure, or altered consciousness — requires emergency evaluation regardless of pending genetic test status
- Failure to thrive with severe dehydration or electrolyte imbalance in neonates — urgent pediatric assessment required
This panel is a diagnostic tool, not an emergency screening device. If your child experiences any of the above symptoms, proceed immediately to the nearest emergency department. Do not wait for genetic test results.
UAE Regulatory Compliance & Accreditation
- ✓ Federal Decree-Law No. 41 of 2024 (Art. 87): All genetic testing conducted with explicit informed consent; results protected under UAE medical confidentiality statutes.
- ✓ CDS Law 2026 (Minors): Genetic testing of minors requires legal guardian consent and is performed only when clinically indicated for the child's direct benefit. Carrier testing and predictive testing in asymptomatic minors is not performed without DHA ethics committee approval.
- ✓ UAE PDPL (Personal Data Protection Law): All genomic data is stored, processed, and transmitted in compliance with UAE data sovereignty requirements. Patient genetic data is never shared with third parties without explicit written consent.
- ✓ ISO 9001:2015 Certified — Certificate No. INT/EGQ/2509DA/3139. Quality management system audited annually for continuous compliance.
- ✓ DHA Facility License: 9834453 — Licensed for molecular genetic testing and genetic counseling services within the Emirate of Dubai.
- ✓ MOHAP Standards Alignment: All laboratory protocols follow UAE Ministry of Health and Prevention guidelines for clinical genetic testing, including proficiency testing through external quality assessment schemes.
Patient FAQ & Clinical Guidance
Q1: What conditions does the Noonan-RASopathies Panel actually test for, and how long until I receive results?
A: This comprehensive 22-gene next-generation sequencing panel simultaneously analyzes all major genes associated with Noonan syndrome, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome, and neurofibromatosis types 1 and 2, delivering definitive molecular diagnostic results within 3 to 4 weeks. The panel's breadth eliminates the need for sequential single-gene testing, which can take months and cost significantly more. Each report includes variant classification per ACMG/AMP 2026 guidelines, zygosity status, and clinically actionable recommendations for cardiac surveillance, developmental support, and oncologic monitoring where relevant. Post-test genetic counseling is included to help families understand pathogenic findings and recurrence risks for future pregnancies.
س2: هل يمكن إجراء هذا الفحص الجيني للأطفال حديثي الولادة أو الرضع في دولة الإمارات؟
ج: يمكن إجراء فحص لوحة نونان ومتلازمات راس الجينية للأطفال حديثي الولادة والرضع في جميع أنحاء الإمارات العربية المتحدة بشرط الحصول على موافقة الوالدين أو الوصي القانوني ووجود مؤشر سريري واضح. يُستخدم الفحص لتأكيد التشخيص لدى الرضع الذين يظهرون علامات سريرية مثل عيوب القلب الخلقية، أو ملامح وجهية مميزة، أو تأخر في النمو. يتم سحب عينة الدم عبر وخز الكعب أو الوريد المحيطي بواسطة أخصائي سحب دم أطفال معتمد. تخضع جميع إجراءات الفحص الجيني للقاصرين لقانون الخدمات التشخيصية والعلاجية لعام 2026 وتتطلب تقييماً أخلاقياً لضمان أن الفحص يصب في المصلحة الفضلى للطفل.
Q3: What happens if my result is negative or shows a variant of uncertain significance (VUS)?
A: A negative result on the Noonan-RASopathies NGS panel does not entirely exclude a clinical diagnosis, as non-coding deep intronic variants, epigenetic modifications, or novel genes not yet included in the panel may still be responsible for the observed phenotype. In cases where a variant of uncertain significance (VUS) is identified, our laboratory provides detailed in silico prediction data, population frequency analysis, and family segregation studies to refine interpretation over time. We offer complimentary variant reclassification reviews annually as new scientific evidence emerges, ensuring your report remains clinically relevant. Your genetic counselor will discuss the implications of negative and VUS results, recommend any additional testing if clinically indicated, and coordinate referrals to specialist clinics within the UAE for ongoing management.
Book Your Noonan-RASopathies Panel Today
Home Collection Available Across All Emirates | 3–4 Week TAT | 3000 AED | Insurance Billing Support
DHA Facility License: 9834453 | ISO 9001:2015 (INT/EGQ/2509DA/3139) | Federal Decree-Law No. 41/2024 Compliant
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians